Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Vagus Nerve Stimulation Devices Market by Product Type (Implantable VNS Devices, External VNS Devices) and by End User (Hospitals, Ambulatory Surgical Centers): Global Opportunity Analysis and Industry Forecast, 2023-2032

A04153

Pages: NA

Charts: NA

Tables: NA

Vagus nerve stimulation device is referred to as a pacemaker for the brain, which stimulates the vagus nerve with the help of electrical impulses. The device is located under the skin on the chest wall and electrical impulse passes through a wire to the vagus nerve in the neck. This vagus nerve controls the functions of the body, which are not controlled voluntarily (for example, the heart rate).

Rise in prevalence of neurological and cardiovascular disorders, increase in geriatric population, growth in support from government and private organizations, and introduction of favorable reimbursement policies drive the market. However, high cost of these devices and complications associated with vagus nerve stimulation restrain the market growth. Furthermore, high adoption rate of minimally invasive VNS procedures and development of next-generation therapies for neurological disorders drive the market growth during the forecast period.

The carotid artery stents market is segmented based on product type, end user, and region. Based on product type, it is bifurcated into balloon expandable stents and self-expanding stents. On the basis of material, the market is classified into implantable VNS devices and external VNS devices. On the basis of end user, the market is divided into hospitals, and ambulatory surgical centers. By geography, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in this market include LivaNova Plc., EnteroMedics Inc., Beijing Pharmaceutical Group Co., Ltd., BioControl Medical (B.C.M) Ltd., and electroCore LLC.

Key Benefits for Stakeholders

  • The study provides an in-depth analysis of the global vagus nerve stimulation device market with current trends and future estimations to elucidate the imminent investment pockets.
  • The report provides information about the current and upcoming trends in the market  which helps to determine the prevailing opportunities.
  • Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
  • Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale are provided.
  • Key market players within the market are profiled in this report and their strategies are analyzed thoroughly, which help to understand the competitive outlook of the market.

Key Market Segments

  • By Product Type
    • Implantable VNS Devices
    • External VNS Devices
  • By End User
    • Hospitals
    • Ambulatory Surgical Centers


Key Market Players

  • Boston Scientific Corporation
  • NeuroSigma
  • BioControl Medical
  • Beckman Coulter
  • Cyberonics
  • Nevro Corp
  • LivaNova
  • Medtronic
  • GM Electromedicina
  • St. Jude Medical
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: VAGUS NERVE STIMULATION DEVICES MARKET, BY PRODUCT TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product Type

    • 4.2. Implantable VNS Devices

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. External VNS Devices

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: VAGUS NERVE STIMULATION DEVICES MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Hospitals

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Ambulatory Surgical Centers

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: VAGUS NERVE STIMULATION DEVICES MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product Type

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S.

        • 6.2.5.1 Market size and forecast, product type

        • 6.2.5.2 Market size and forecast, end user

      • 6.2.6. Canada

        • 6.2.6.1 Market size and forecast, product type

        • 6.2.6.2 Market size and forecast, end user

      • 6.2.7. Mexico

        • 6.2.7.1 Market size and forecast, product type

        • 6.2.7.2 Market size and forecast, end user

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product Type

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France

        • 6.3.5.1 Market size and forecast, product type

        • 6.3.5.2 Market size and forecast, end user

      • 6.3.6. Germany

        • 6.3.6.1 Market size and forecast, product type

        • 6.3.6.2 Market size and forecast, end user

      • 6.3.7. Italy

        • 6.3.7.1 Market size and forecast, product type

        • 6.3.7.2 Market size and forecast, end user

      • 6.3.8. Spain

        • 6.3.8.1 Market size and forecast, product type

        • 6.3.8.2 Market size and forecast, end user

      • 6.3.9. UK

        • 6.3.9.1 Market size and forecast, product type

        • 6.3.9.2 Market size and forecast, end user

      • 6.3.10. Russia

        • 6.3.10.1 Market size and forecast, product type

        • 6.3.10.2 Market size and forecast, end user

      • 6.3.11. Rest Of Europe

        • 6.3.11.1 Market size and forecast, product type

        • 6.3.11.2 Market size and forecast, end user

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product Type

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China

        • 6.4.5.1 Market size and forecast, product type

        • 6.4.5.2 Market size and forecast, end user

      • 6.4.6. Japan

        • 6.4.6.1 Market size and forecast, product type

        • 6.4.6.2 Market size and forecast, end user

      • 6.4.7. India

        • 6.4.7.1 Market size and forecast, product type

        • 6.4.7.2 Market size and forecast, end user

      • 6.4.8. South Korea

        • 6.4.8.1 Market size and forecast, product type

        • 6.4.8.2 Market size and forecast, end user

      • 6.4.9. Australia

        • 6.4.9.1 Market size and forecast, product type

        • 6.4.9.2 Market size and forecast, end user

      • 6.4.10. Thailand

        • 6.4.10.1 Market size and forecast, product type

        • 6.4.10.2 Market size and forecast, end user

      • 6.4.11. Malaysia

        • 6.4.11.1 Market size and forecast, product type

        • 6.4.11.2 Market size and forecast, end user

      • 6.4.12. Indonesia

        • 6.4.12.1 Market size and forecast, product type

        • 6.4.12.2 Market size and forecast, end user

      • 6.4.13. Rest of Asia Pacific

        • 6.4.13.1 Market size and forecast, product type

        • 6.4.13.2 Market size and forecast, end user

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product Type

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil

        • 6.5.5.1 Market size and forecast, product type

        • 6.5.5.2 Market size and forecast, end user

      • 6.5.6. South Africa

        • 6.5.6.1 Market size and forecast, product type

        • 6.5.6.2 Market size and forecast, end user

      • 6.5.7. Saudi Arabia

        • 6.5.7.1 Market size and forecast, product type

        • 6.5.7.2 Market size and forecast, end user

      • 6.5.8. UAE

        • 6.5.8.1 Market size and forecast, product type

        • 6.5.8.2 Market size and forecast, end user

      • 6.5.9. Argentina

        • 6.5.9.1 Market size and forecast, product type

        • 6.5.9.2 Market size and forecast, end user

      • 6.5.10. Rest of LAMEA

        • 6.5.10.1 Market size and forecast, product type

        • 6.5.10.2 Market size and forecast, end user

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. LivaNova

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Boston Scientific Corporation

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Nevro Corp

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Medtronic

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Cyberonics

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. St. Jude Medical

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. NeuroSigma

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Beckman Coulter

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. BioControl Medical

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. GM Electromedicina

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL VAGUS NERVE STIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 2. VAGUS NERVE STIMULATION DEVICES MARKET FOR IMPLANTABLE VNS DEVICES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. VAGUS NERVE STIMULATION DEVICES MARKET FOR EXTERNAL VNS DEVICES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL VAGUS NERVE STIMULATION DEVICES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 5. VAGUS NERVE STIMULATION DEVICES MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. VAGUS NERVE STIMULATION DEVICES MARKET FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. VAGUS NERVE STIMULATION DEVICES MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. NORTH AMERICA VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 9. NORTH AMERICA VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 10. NORTH AMERICA VAGUS NERVE STIMULATION DEVICES, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 11. U.S. VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 12. U.S. VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 13. CANADA VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 14. CANADA VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 15. MEXICO VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 16. MEXICO VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 17. EUROPE VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 18. EUROPE VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 19. EUROPE VAGUS NERVE STIMULATION DEVICES, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 20. FRANCE VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 21. FRANCE VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 22. GERMANY VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 23. GERMANY VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. ITALY VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 25. ITALY VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. SPAIN VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 27. SPAIN VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 28. UK VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 29. UK VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. RUSSIA VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 31. RUSSIA VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 32. REST OF EUROPE VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 33. REST OF EUROPE VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 34. ASIA-PACIFIC VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 35. ASIA-PACIFIC VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC VAGUS NERVE STIMULATION DEVICES, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 37. CHINA VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 38. CHINA VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. JAPAN VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 40. JAPAN VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 41. INDIA VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 42. INDIA VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. SOUTH KOREA VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 44. SOUTH KOREA VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. AUSTRALIA VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 46. AUSTRALIA VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 47. THAILAND VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 48. THAILAND VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. MALAYSIA VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 50. MALAYSIA VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 51. INDONESIA VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 52. INDONESIA VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 53. REST OF ASIA PACIFIC VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 54. REST OF ASIA PACIFIC VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. LAMEA VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 56. LAMEA VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 57. LAMEA VAGUS NERVE STIMULATION DEVICES, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 58. BRAZIL VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 59. BRAZIL VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 60. SOUTH AFRICA VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 61. SOUTH AFRICA VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. SAUDI ARABIA VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 63. SAUDI ARABIA VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. UAE VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 65. UAE VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 66. ARGENTINA VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 67. ARGENTINA VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. REST OF LAMEA VAGUS NERVE STIMULATION DEVICES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 69. REST OF LAMEA VAGUS NERVE STIMULATION DEVICES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. LIVANOVA: KEY EXECUTIVES
  • TABLE 71. LIVANOVA: COMPANY SNAPSHOT
  • TABLE 72. LIVANOVA: OPERATING SEGMENTS
  • TABLE 73. LIVANOVA: PRODUCT PORTFOLIO
  • TABLE 74. LIVANOVA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 75. BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
  • TABLE 76. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • TABLE 77. BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
  • TABLE 78. BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
  • TABLE 79. BOSTON SCIENTIFIC CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 80. NEVRO CORP: KEY EXECUTIVES
  • TABLE 81. NEVRO CORP: COMPANY SNAPSHOT
  • TABLE 82. NEVRO CORP: OPERATING SEGMENTS
  • TABLE 83. NEVRO CORP: PRODUCT PORTFOLIO
  • TABLE 84. NEVRO CORP: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 85. MEDTRONIC: KEY EXECUTIVES
  • TABLE 86. MEDTRONIC: COMPANY SNAPSHOT
  • TABLE 87. MEDTRONIC: OPERATING SEGMENTS
  • TABLE 88. MEDTRONIC: PRODUCT PORTFOLIO
  • TABLE 89. MEDTRONIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 90. CYBERONICS: KEY EXECUTIVES
  • TABLE 91. CYBERONICS: COMPANY SNAPSHOT
  • TABLE 92. CYBERONICS: OPERATING SEGMENTS
  • TABLE 93. CYBERONICS: PRODUCT PORTFOLIO
  • TABLE 94. CYBERONICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 95. ST. JUDE MEDICAL: KEY EXECUTIVES
  • TABLE 96. ST. JUDE MEDICAL: COMPANY SNAPSHOT
  • TABLE 97. ST. JUDE MEDICAL: OPERATING SEGMENTS
  • TABLE 98. ST. JUDE MEDICAL: PRODUCT PORTFOLIO
  • TABLE 99. ST. JUDE MEDICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 100. NEUROSIGMA: KEY EXECUTIVES
  • TABLE 101. NEUROSIGMA: COMPANY SNAPSHOT
  • TABLE 102. NEUROSIGMA: OPERATING SEGMENTS
  • TABLE 103. NEUROSIGMA: PRODUCT PORTFOLIO
  • TABLE 104. NEUROSIGMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 105. BECKMAN COULTER: KEY EXECUTIVES
  • TABLE 106. BECKMAN COULTER: COMPANY SNAPSHOT
  • TABLE 107. BECKMAN COULTER: OPERATING SEGMENTS
  • TABLE 108. BECKMAN COULTER: PRODUCT PORTFOLIO
  • TABLE 109. BECKMAN COULTER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110. BIOCONTROL MEDICAL: KEY EXECUTIVES
  • TABLE 111. BIOCONTROL MEDICAL: COMPANY SNAPSHOT
  • TABLE 112. BIOCONTROL MEDICAL: OPERATING SEGMENTS
  • TABLE 113. BIOCONTROL MEDICAL: PRODUCT PORTFOLIO
  • TABLE 114. BIOCONTROL MEDICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. GM ELECTROMEDICINA: KEY EXECUTIVES
  • TABLE 116. GM ELECTROMEDICINA: COMPANY SNAPSHOT
  • TABLE 117. GM ELECTROMEDICINA: OPERATING SEGMENTS
  • TABLE 118. GM ELECTROMEDICINA: PRODUCT PORTFOLIO
  • TABLE 119. GM ELECTROMEDICINA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL VAGUS NERVE STIMULATION DEVICES MARKET SEGMENTATION
  • FIGURE 2. GLOBAL VAGUS NERVE STIMULATION DEVICES MARKET
  • FIGURE 3. SEGMENTATION VAGUS NERVE STIMULATION DEVICES MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN VAGUS NERVE STIMULATION DEVICES MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALVAGUS NERVE STIMULATION DEVICES MARKET
  • FIGURE 11. VAGUS NERVE STIMULATION DEVICES MARKET SEGMENTATION, BY PRODUCT TYPE
  • FIGURE 12. VAGUS NERVE STIMULATION DEVICES MARKET FOR IMPLANTABLE VNS DEVICES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. VAGUS NERVE STIMULATION DEVICES MARKET FOR EXTERNAL VNS DEVICES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. VAGUS NERVE STIMULATION DEVICES MARKET SEGMENTATION, BY END USER
  • FIGURE 15. VAGUS NERVE STIMULATION DEVICES MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. VAGUS NERVE STIMULATION DEVICES MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 18. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 19. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 20. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 21. COMPETITIVE DASHBOARD
  • FIGURE 22. COMPETITIVE HEATMAP: VAGUS NERVE STIMULATION DEVICES MARKET
  • FIGURE 23. TOP PLAYER POSITIONING,2022
  • FIGURE 24. LIVANOVA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 25. LIVANOVA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 26. LIVANOVA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 27. BOSTON SCIENTIFIC CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 28. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 29. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 30. NEVRO CORP: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 31. NEVRO CORP: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 32. NEVRO CORP: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 33. MEDTRONIC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. MEDTRONIC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. MEDTRONIC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. CYBERONICS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. CYBERONICS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. CYBERONICS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. ST. JUDE MEDICAL: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. ST. JUDE MEDICAL: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. ST. JUDE MEDICAL: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. NEUROSIGMA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. NEUROSIGMA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. NEUROSIGMA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. BECKMAN COULTER: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. BECKMAN COULTER: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. BECKMAN COULTER: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. BIOCONTROL MEDICAL: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. BIOCONTROL MEDICAL: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. BIOCONTROL MEDICAL: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. GM ELECTROMEDICINA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. GM ELECTROMEDICINA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. GM ELECTROMEDICINA: REVENUE SHARE, BY REGION, 2032 (%)

Purchase Full Report of
Vagus Nerve Stimulation Devices Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue